OBIO® in the Community
On April 9, 2018, OBIO hosted Pfizer Global for a workshop and partnering day at ONRamp in the Banting Institute.
OBIO and Blakes hosted OBIO's third annual pre-RESI networking event, connecting high potential companies with global investors. Over 100 international investors, local investors and strategics, as well as executives from high potential Ontario health science companies
OBIO - in partnership with Accel-Rx - hosted the Niagara Health Science Emerging Company Forum, which brought together CEOs and senior executives from high potential Canadian health science companies with senior leadership from American investors and strategics.
On October 24th, OBIO hosted Health Economics Day workshop in partnership with St. Michael’s Hospital.
The workshop took place in the auditorium at the Li Ka Shing Knowledge Institute and featured four sessions: a moderated panel discussion with four panellists, followed by three presentations by three health economics experts.
Recently, the Minister of Innovation, Science and Economic Development launched a cross country tour to introduce the nine supercluster proposals that have been shortlisted by the federal government for the Innovation Superclusters Initiative.
Grant Burns, OBIO's Public Affairs and Communications Manager, has listed the 9 proposals and provided commentary and analysis on how they relate to the health technology sector.
On October 2nd, Andrew Hutchinson, External Research & Scouting Lead for Alexion Pharmaceuticals, provided his insights on the strategic partnering process between early stage therapeutic companies and big pharma to the OBIO community.
OBIO's Dr. Klaus Fiebig, VP Strategic Programs, recently attended an insightful workshop on the upcoming regulatory changes affecting the CE mark. Obtaining the CE mark is a "mandatory hurdle" to access the $56B EU market, and the new regulatory changes present an opportunity for medical device companies.
Should these changes adjust your CE mark milestones? Read the Klaus' analysis and decide.
On July 11th, Grant Blevins of FCA Venture Partners in Nashville Tennessee, returned to OBIO via webinar to give his second workshop on digital health. Grant focused on the "Why, When, & How Much" that early stage companies should consider when raising capital.
In the latest issue of Biotechnology Focus, OBIO President and CEO Gail Garland contributed a special report.
Anchor Companies and 'Sticky Capital': A prescription for attracting bioscience investment to Ontario
Gail Garland, President and CEO of OBIO, travelled to San Diego for BIO 2017, one of the largest annual conventions in the biotechnology industry.
Enjoy this weeks blog on Finding the Right Candidate by Sean Peel, H2BB™ Business Development Manager & Ryan Ball, H2BB™ Program Associate.
On May 12th, Grant Blevins and Andrew Bouldin of FCA Venture Partners, of Nashville, Tennessee, gave a workshop on the financing landscape of the digital health industry. FCA Venture Partners provides early stage capital for innovative digital health companies focusing on B2B SaaS.
Enjoy this week's blog by Sean Peel, OBIO's H2BB™ Business Development Manager.
Enjoy Part II of the RESI Recap series authored by OBIO's Klaus Fiebig, VP Strategic Programs
OBIO's own VP Strategic Programs, Klaus Fiebig, shares his impressions and advice garnered from RESI on MaRS last week highlighting some of the trends and sentiments about early stage fundraising.
OBIO kicked off its 2017 Capital Access Advisory Program (CAAP®) on March 29, 2017, hosted at sponsor Norton Rose Fulbright LLP (NRF) Canada, just as Toronto’s first inaugural Health Innovation Week launches
The Ontario Bioscience Innovation Organization Leadership Summit Hosts Top Health Science Minds to Define Future of the Industry
The Ontario Bioscience Innovation Organization Announces New Public Relations & Communications Services Member Benefit
OBIO is pleased to announce a call for applications for the 2017 OBIO Capital Access Advisory Program (CAAP®).
Christine Charette, SVP Strategic Finance, OBIO offers her insights into the premiere conference for MedTech companies.
Christine Charette, SVP Strategic Finance, OBIO shares her advice on navigating the Health Science Investor in Part 2 of the Combined Conference Insights on RESI Boston & Digital Medicine Connect at BioPharm America September 13,14,15 2016
For the full PDF of the article click here
Christine Charette, SVP Strategic Finance, OBIO offers her perspective on the RESI conference and BioPharm America.
For a PDF of the full article, click here
The article titled "From Opportunities To ROI – Adopting Innovation In Canada" focusses on the key recommendations of the OBIO report “How Canada Should be Engaging in a $9 Trillion Dollar Health Economy.”
Click here for the full article
OBIO is a not-for-profit organization committed to the development of an integrated health innovation economy for the province. Its report, How Canada Should be Engaging in a $9 Trillion Dollar Health Economy, was based on surveys and interviews with 125 CEOs of health science companies around the country. It makes recommendations aimed to ensure Canadians get the economic and patient benefits from being competitive in the global health market.
OBIO initiated the Eastern leg of its Provincewide Tour in Ottawa to promote their recently released report “How Canada Should be Engaging in a $9 Trillion Dollar Health Economy."
Tuesday in a joint announcement the Minister of Innovation Science and Economic Development, Minister of Science, and the Minister of Small Business and Tourism unveiled 6 action areas to build an innovative Canada.
For OBIO's comments on report, click here.
On Tuesday June 16, 2016 the first steps began towards the development of a Canadian National Inclusive Innovation Agenda. In a joint announcement the Minister of Innovation Science and Economic Development, Minister of Science, and the Minister of Small Business and Tourism unveiled 6 action areas to build an innovative Canada.